| 王志鹏,杨宏伟,何立芳,等.利妥昔单抗治疗中高风险原发性膜性肾病的疗效和安全性分析[J].安徽医药,2025,29(11):2317-2320. |
| 利妥昔单抗治疗中高风险原发性膜性肾病的疗效和安全性分析 |
| Exploring the efficacy and safety of rituximab in managing medium to high-risk primary membranous nephropathy |
| |
| DOI：10.3969/j.issn.1009-6469.2025.11.043 |
| 中文关键词: 肾小球肾炎，膜性 利妥昔单抗 免疫疗法 抗磷脂酶 A2受体抗体 蛋白尿 抗原， CD |
| 英文关键词: Glomerulonephritis, membranous Rituximab Immunotherapy Anti PLA2R antibody Proteinuria Antigens, CD |
| 基金项目: |
|
| 摘要点击次数: 669 |
| 全文下载次数: 144 |
| 中文摘要: |
| 目的分析利妥昔单抗( RTX)治疗中高风险原发性膜性肾病(PMN)的疗效和安全性。方法回顾性分析 2019年 12月至 2021年 12月于唐山市人民医院 50例接受 RTX治疗中高风险 PMN病人的临床资料。结果 50例中高风险 PMN病人男性 18例，女性 32例，年龄( 38.1±10.2)岁。病人常规治疗［血管紧张素 Ⅱ受体阻滞剂( ARB)类药物］基础上给予 RTX治疗( 4剂或 2剂)； 50例病人 RTX治疗前后血肌酐差异无统计学意义( P>0.05)血清白蛋白较治疗前显著升高(P<0.05)24 h尿蛋白定量、抗磷脂酶 A2受体( PLA2R)抗体、分化抗原( CD)19+B细胞水平较治疗，前明显降低( P<0.05)。随访 1年，结果有，22例达到完全缓解( 44%)，15例达到部分缓解( 30%)13例未缓解( 26%)。输注 RTX过程中有 3例病人出现心悸，经减慢滴速后缓解，随访期间未发现特殊药物不良反应。结论 R，TX治疗中高风险 PMN病人效果显著，安全性良好。 |
| 英文摘要: |
| Objective To analyze the therapeutic outcomes and safety associated with the use of rituximab in individuals suffering from medium to high-risk primary membranous nephropathy (PMN).Methods A retrospective analysis was conducted on the clinical data of 50 patients with medium to high-risk PMN who received rituximab (RTX) treatment in The People's Hospital of Tangshan from December 2019 to December 2021.Results Among the 50 PMN patients, there were 18 males and 32 females, aged (38.1±10.2) yearsold. RTX treatment (4 or 2 doses) was provided on the basis of routine treatment (ARB drugs) for patients. The comparison of blood cre-atinine levels before and after RTX treatment in 50 patients revealed no statistically significant difference (P>0.05). Serum albumin sig-nificantly increased compared to before treatment (P<0.05), while 24-hour urine protein quantification, anti PLA2R antibody, and CD19+B cell levels significantly decreased compared to before treatment (P<0.05). Following up for one year, complete response wasachieved by 22 patients (44%), partial response by 15 patients (30%), and no response by 13 patients (26%).Conclusion Rituximab has a significant effect on treating patients with medium to high-risk PMN. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
